Physician profile
John M Prince
NPI 1861501991
$117,452.43
in general payments reported to CMS, 2019-2025
37 companies · $20K in 2025
The $20K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $6,237 · 2021: $21K · 2022: $22K · 2023: $17K · 2024: $20K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Food and Beverage: $10K · Travel and Lodging: $1,532 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,432.67 |
| Food and Beverage | $10,017.83 |
| Travel and Lodging | $1,531.92 |
| Education | $233.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $79,789.31 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,435.95 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $11,223.08 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,761.37 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $1,531.45 | 2019-2025 | Arikayce, Brinsupri |
| Amgen INC. | $1,054.07 | 2022-2025 | Tezspire, Tavneos |
| Grifols USA, LLC | $405.85 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $361.03 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Genzyme Corporation | $343.37 | 2022-2025 | |
| Electromed, INC. | $294.80 | 2019-2025 | Smartvest |
| Baxter Healthcare | $226.33 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $193.41 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.73 | 2020-2025 | Glassia |
| Mylan Specialty L.P. | $151.24 | 2022-2024 | Yupelri |
| Philips North America LLC | $130.05 | 2019-2024 | (Ak6) Vest Therapy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $122.15 | 2021-2023 | |
| United Therapeutics Corporation | $117.67 | 2023-2025 | Tyvaso, Tyvaso, Orenitram |
| Galvanize Therapeutics, INC | $115.58 | 2025 | Aliya System |
| Janssen Pharmaceuticals, INC | $113.80 | 2019 | |
| Sunovion Pharmaceuticals INC. | $102.12 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $94.95 | 2024 | |
| Inogen, INC. | $82.16 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Ani Pharmaceuticals, INC. | $75.68 | 2023-2024 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $71.76 | 2024-2025 | Keytruda, Zerbaxa, Capvaxive |
| La Jolla Pharmaceutical Company | $63.78 | 2024-2025 | Giapreza |
| Advanced Respiratory, INC | $61.64 | 2019-2021 | |
| Verona Pharma, INC. | $60.88 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $51.00 | 2022-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Viatris Specialty LLC | $43.51 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $41.45 | 2020-2025 | Acthar |
| Phadia US INC. | $33.91 | 2019-2023 | Immunocap |
| Gilead Sciences, INC. | $32.25 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $21.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.39 | 2022 | |
| Mallinckrodt Enterprises LLC | $18.40 | 2019 | |
| Shire North American Group INC | $17.79 | 2019 | |
| Harmony Biosciences LLC | $16.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.